Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO)

The role of adjuvant radiotherapy and/or chemotherapy in the primary treatment of endometrial cancer with a high risk of recurrence has still not been conclusively determined. The results of 3 large randomized controlled studies on different aspects of this issue have been published in full in recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Emons, Günter, Tempfer, Clemens, Battista, Marco Johannes, Mustea, Alexander, Vordermark, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924345/
https://www.ncbi.nlm.nih.gov/pubmed/31875857
http://dx.doi.org/10.1055/a-1019-7720
_version_ 1783481711554723840
author Emons, Günter
Tempfer, Clemens
Battista, Marco Johannes
Mustea, Alexander
Vordermark, Dirk
author_facet Emons, Günter
Tempfer, Clemens
Battista, Marco Johannes
Mustea, Alexander
Vordermark, Dirk
author_sort Emons, Günter
collection PubMed
description The role of adjuvant radiotherapy and/or chemotherapy in the primary treatment of endometrial cancer with a high risk of recurrence has still not been conclusively determined. The results of 3 large randomized controlled studies on different aspects of this issue have been published in full in recent months, and the relevant results are analyzed here.
format Online
Article
Text
id pubmed-6924345
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-69243452019-12-23 Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO) Emons, Günter Tempfer, Clemens Battista, Marco Johannes Mustea, Alexander Vordermark, Dirk Geburtshilfe Frauenheilkd The role of adjuvant radiotherapy and/or chemotherapy in the primary treatment of endometrial cancer with a high risk of recurrence has still not been conclusively determined. The results of 3 large randomized controlled studies on different aspects of this issue have been published in full in recent months, and the relevant results are analyzed here. Georg Thieme Verlag KG 2019-12 2019-12-11 /pmc/articles/PMC6924345/ /pubmed/31875857 http://dx.doi.org/10.1055/a-1019-7720 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Emons, Günter
Tempfer, Clemens
Battista, Marco Johannes
Mustea, Alexander
Vordermark, Dirk
Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO)
title Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO)
title_full Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO)
title_fullStr Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO)
title_full_unstemmed Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO)
title_short Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO)
title_sort adjuvant radiotherapy and/or chemotherapy for endometrial cancer, status as at 2019: opinion of the uterus commission of the gynecological oncology working group (ago)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924345/
https://www.ncbi.nlm.nih.gov/pubmed/31875857
http://dx.doi.org/10.1055/a-1019-7720
work_keys_str_mv AT emonsgunter adjuvantradiotherapyandorchemotherapyforendometrialcancerstatusasat2019opinionoftheuteruscommissionofthegynecologicaloncologyworkinggroupago
AT tempferclemens adjuvantradiotherapyandorchemotherapyforendometrialcancerstatusasat2019opinionoftheuteruscommissionofthegynecologicaloncologyworkinggroupago
AT battistamarcojohannes adjuvantradiotherapyandorchemotherapyforendometrialcancerstatusasat2019opinionoftheuteruscommissionofthegynecologicaloncologyworkinggroupago
AT musteaalexander adjuvantradiotherapyandorchemotherapyforendometrialcancerstatusasat2019opinionoftheuteruscommissionofthegynecologicaloncologyworkinggroupago
AT vordermarkdirk adjuvantradiotherapyandorchemotherapyforendometrialcancerstatusasat2019opinionoftheuteruscommissionofthegynecologicaloncologyworkinggroupago
AT adjuvantradiotherapyandorchemotherapyforendometrialcancerstatusasat2019opinionoftheuteruscommissionofthegynecologicaloncologyworkinggroupago

Ejemplares similares